ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,556 GBX | +0.05% |
|
+1.75% | +18.45% |
| 06:29pm | European Equities Close Lower in Wednesday Trading | MT |
| 01:57pm | ASTRAZENECA : Deutsche Bank sticks Neutral | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.45% | 247B | |
| +54.63% | 815B | |
| +44.25% | 654B | |
| -6.21% | 354B | |
| +21.29% | 337B | |
| +10.99% | 302B | |
| +2.09% | 229B | |
| +13.03% | 219B | |
| +8.80% | 171B | |
| -4.71% | 159B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Breast Cancer Combo Fails to Extend Overall Survival in Late-stage Trial
